SLU-PP-332
SLU-PP-332 is supplied as a pan-agonist of the estrogen-related receptors (ERR-alpha/beta/gamma) for mitochondrial and energy-metabolism pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
SLU-PP-332 in research
SLU-PP-332 is supplied as a pan-agonist of the estrogen-related receptors (ERR-alpha/beta/gamma) for mitochondrial and energy-metabolism pathway research.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for SLU-PP-332 before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
No supplier listing text is on file yet for this item.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
No human clinical trials of SLU-PP-332 have been reported in the peer-reviewed literature to date. There is no controlled human efficacy or safety data, and the existing evidence base is confined to laboratory and animal models.
SLU-PP-332 is described in published research as a synthetic agonist of the estrogen-related receptors (ERRs), studied as an exercise mimetic in animal models. Billon and colleagues reported that the compound alleviated features of metabolic syndrome in mice (Billon et al., Journal of Pharmacology and Experimental Therapeutics, 2024, doi:10.1124/jpet.123.001733). These findings are preclinical and have not been confirmed in humans.
SLU-PP-332 is discussed in fitness and longevity communities as an exercise-mimetic candidate, typically based on the rodent studies rather than any human data. Such discussion is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
SLU-PP-332 is not approved by the FDA for any use and is an investigational research compound. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about SLU-PP-332
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Billon C, et al. Synthetic ERR-alpha/beta/gamma Agonist Induces an ERR-alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. https://doi.org/10.1021/acschembio.2c00720
- Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024. https://doi.org/10.1124/jpet.123.001733